Welcome to our dedicated page for Pediatrix Medical Group SEC filings (Ticker: MD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Haddock David reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group EVP David Haddock received new equity awards. On 2026-06-22, he was granted 20,036 shares of common stock at no cost as restricted shares under the company’s incentive compensation plan.
He also received 51,000 Performance Share Units, each tied to one common share. These PSUs vest after three years only if both service and stock performance conditions are met. Shares are earned in one-third increments based on Pediatrix’s stock trading at 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date.
Pediatrix Medical Group, Inc. executive David Haddock, who serves as EVP, General Counsel and Corporate Secretary, submitted an initial Form 3 insider ownership report. The filing lists no transactions or derivative positions, functioning as a baseline disclosure of his status as a reporting officer.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported bona fide gifts of 36,814 shares of common stock. The transactions on June 9, 2026 moved 18,407 shares to a family trust and 18,407 shares from her direct holdings. After these transfers, she holds 78,059 shares directly and 111,831 shares indirectly through the trust, with beneficial interest limited to her pecuniary stake.
Pediatrix Medical Group EVP, CFO and Treasurer Kasandra H. Rossi received 31,800 restricted shares of common stock as an annual equity award under the company’s incentive compensation plan. The award vests 25% on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029. In connection with vesting of prior awards, 3,701 restricted shares were withheld to cover taxes. After these transactions, Rossi directly holds 105,100 common shares.
Pediatrix Medical Group Chief Executive Officer Mark S. Ordan reported a series of equity compensation adjustments and tax-related share withholdings. He received 127,198 restricted shares on June 1, 2026 at no cost under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, tied to an annual equity award. A portion of these restricted shares is scheduled to vest 25% on June 1, 2027, 25% on June 1, 2028 and 50% on June 1, 2029, subject to the plan’s terms.
The filing also shows 19,119 restricted shares of common stock disposed of on June 1, 2026 at a price of $21.54 per share, representing shares withheld to cover taxes upon vesting. In addition, 97,174 restricted shares were granted on June 2, 2026 and 97,174 shares were returned to the issuer the same day. This pair of transactions reflects a revision to a 194,347-share annual equity award originally granted on June 1, 2025 so it complies with the plan’s annual award limitations, while preserving the intended vesting schedule. After these transactions, Ordan directly holds 313,710 shares of Pediatrix Medical Group common stock.
Pediatrix Medical Group EVP and Chief Investment & Strategy Officer Don Gregory Neeb reported routine equity compensation activity. He received a grant of 63,888 restricted shares of common stock under the company’s Second Amended and Restated 2008 Incentive Compensation Plan as part of an annual equity award.
According to the vesting schedule, 25% of these restricted shares will vest on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029, subject to the plan’s terms. In a related tax-withholding disposition, 8,003 restricted shares were withheld to cover taxes upon vesting of shares. After these entries, Neeb directly holds 145,234 Pediatrix common shares.
Pediatrix Medical Group EVP Mary Ann E. Moore reported a routine share withholding for taxes. On the vesting of restricted stock, 11,944 common shares were withheld at $21.54 per share to cover tax obligations, classified as a tax-withholding disposition.
After this event, she directly holds 96,466 common shares. A separate trust, for which she and her spouse serve as trustees, holds 93,424 common shares indirectly; she disclaims beneficial interest in those shares beyond her pecuniary interest.
Pediatrix Medical Group director-linked trust sells shares
A trust associated with director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group common stock in an open-market transaction at a weighted average price of $23.75 per share, with individual trade prices ranging from $23.55 to $23.85.
The shares were held by The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees and members of her immediate family are beneficiaries. Following the sale, the trust reported no remaining Pediatrix shares, while Weis directly holds 18,623 shares.
Pediatrix Medical Group director Thomas McEachin reported charitable-style transfers of company stock. On May 13, 2026, he made bona fide gifts totaling 22,854 shares of Pediatrix common stock. One 11,427-share gift involved a trust where he and his spouse serve as trustees and beneficiaries, and another 11,427-share gift involved directly held shares.
After these transactions, McEachin reports indirect ownership of 66,073 shares through the trust and continued direct ownership of 7,196 shares. These are non-cash, gift transfers rather than open-market sales or purchases, and do not change his role as a director.
Pediatrix Medical Group, Inc. submitted a Form 144 notice via Robert W. Baird & Co. proposing the resale of restricted common shares tied to compensatory vesting.
The excerpt lists proposed shares associated with four vesting dates: 07/12/2021 (2,926 shares), 07/12/2023 (3,777), 05/11/2024 (10,965), and 05/09/2025 (18,360); aggregate appears as 36,028 shares.